Chimeric Therapeutics has strengthened its leadership, appointing experienced biotechnology executive Dr Bradley Glover as Non-Executive Director and Chair, and naming a new Chief Financial Officer, as part of a broader governance refresh.

A new prostate cancer imaging technology from Clarity Pharmaceuticals (ASX:CU6) is showing promise in improving the detection of recurrent disease, after results from a comparative clinical study indicated it may outperform the current standard of care.

Emyria’s (ASX:EMD) push to scale its insurer-backed mental health services across Australia has taken a significant step forward, with Medibank expanding its funding agreement to support patients at the company’s new Mornington Peninsula clinic in Victoria.

CSL has reported a slip in first-half results for 2026, shaped by policy headwinds, restructuring charges and asset impairments, even as the company accelerates a wide-ranging transformation aimed at restoring growth and long-term value.

The therapeutic antibody developer Patrys (ASX:PAB) has announced the appointment of Dr Samantha South as its new Chief Executive Officer, effective 16 February 2026.

Amplia Therapeutics (ASX:ATX) has taken a step forward in its clinical expansion strategy, announcing the opening of two U.S. trial sites for its AMPLICITY pancreatic cancer study.

A new peer-reviewed study published in PLOS One has provided evidence that pentosan polysulfate sodium delivers sustained clinical, functional, and structural benefits in osteoarthritis, reinforcing its potential as a disease-modifying therapy.

Chimeric Therapeutics (ASX:CHM) has announced that its CHM CDH17 CAR-T program has advanced to Dose Level 3. This is the highest dose tier in the Phase 1 portion of its ongoing trial.

Australian contract research organisation Molecule2Market has appointed Dr Julie Ince-Demetriou as its first Chief Executive Officer, marking a pivotal moment in the company’s evolution as it enters a new phase of growth and operational scale.

Memphasys (ASX:MEM) has reached a major commercial milestone with the Therapeutic Goods Administration granting approval for its Felix System ahead of schedule, clearing the way for immediate sales and clinical deployment across Australia.

Algorae Pharmaceuticals (ASX:1AI) has taken another step in building a diversified commercial medicines platform, finalising a new licensing and supply agreement that broadens its reach beyond oncology into cardiovascular and metabolic disease markets.

Arovella Therapeutics (ASX:ALA) is entering a period of board renewal as the biotechnology company advances toward a critical clinical inflection point.

Immutep (ASX:IMM) has passed a key clinical milestone, achieving 50 per cent patient enrolment in its pivotal global Phase 3 trial evaluating a novel immunotherapy combination for first-line non-small cell lung cancer.

Australia’s nuclear medicine sector is urging the Commonwealth to establish a dedicated national funding stream for radiopharmaceutical cancer therapies.

Neuren Pharmaceuticals said FDA feedback has clarified the regulatory path for NNZ-2591 in HIE and Pitt Hopkins syndrome, supporting continued US development while European uncertainty persists following a negative EMA trend vote on its licensed Rett syndrome therapy, trofinetide.

Trajan Group (ASX:TRJ) has reaffirmed its full-year financial year 2026 guidance after a subdued start to the year gave way to a stronger second quarter, positioning the global analytical science and device group for improved performance in the second half.

Arovella Therapeutics (ASX:ALA) has entered a pivotal new phase of development after securing US Food and Drug Administration acceptance of its Investigational New Drug application for ALA-101.

Ovarian cancer remains notoriously difficult to diagnose at an early stage, with symptoms that are often vague, non-specific and easily mistaken for less serious conditions.